阿夫凯泰对症状性梗阻性肥厚型心肌病心脏结构与功能的影响
SEQUOIA-HCM 三期随机双盲安慰剂对照研究显示,阿夫凯泰在 282 例症状性梗阻性肥厚型心肌病患者中显著降低静息和 Valsalva 左室流出道压差并改善左室舒张功能指标,左室射血分数轻度可逆下降但仍在正常范围。
要点
- 阿夫凯泰显著降低静息和 Valsalva 左室流出道压差,并改善左房容积指数及 e'、E/e' 等舒张功能指标。
- 左室射血分数轻度下降(-4.8%),但仍在正常范围,且洗脱后恢复。
- pVO2、KCCQ-CSS 和 NT-proBNP 的改善与左室流出道压差及舒张功能指标改善相关。
核心结论
- 与安慰剂相比,阿夫凯泰显著改善左室流出道压差和左室舒张功能指标。
- 左室射血分数轻度下降但仍在正常范围,未见显著左室收缩功能不良变化。
研究设计与样本
- SEQUOIA-HCM 为三期、多中心、随机、双盲、安慰剂对照研究,共纳入 282 例症状性梗阻性肥厚型心肌病患者。
- 患者随机接受安慰剂或阿夫凯泰,阿夫凯泰组在 24 周内基于 Valsalva 左室流出道压差和左室射血分数个体化滴定至最多 4 个递增剂量(5-20 mg/日),并连续进行 28 周超声心动图检查。
主要发现
- 24 周内,阿夫凯泰显著降低静息和 Valsalva 左室流出道压差,并改善左房容积指数、侧壁和间隔 e' 速度及侧壁和间隔 E/e'(所有 P ≤ 0.001)。
- 左室收缩末期容积增加、室壁厚度减小(所有 P ≤ 0.003)。
- 左室射血分数轻度可逆下降(-4.8% [95%CI: -6.4% 至 -3.3%];P < 0.001),左室整体环向应变绝对值降低(-3.7% [95%CI: 1.8%-5.6%];P < 0.0010),左室整体纵向应变不变。
- 左室射血分数、左室流出道压差和 E/e' 等指标在洗脱后恢复至基线。
- 在阿夫凯泰组中,pVO2 改善和 NT-proBNP 降低与侧壁 e' 速度及间隔和侧壁 E/e' 改善相关(所有 P < 0.03),KCCQ-CSS 改善与左室流出道压差降低相关(所有 P < 0.001)。
临床怎么用
- 对于症状性梗阻性肥厚型心肌病患者,阿夫凯泰可改善左室流出道梗阻和舒张功能,且左室射血分数轻度下降但仍在正常范围。
- 治疗期间需监测左室射血分数和左室流出道压差,以指导剂量滴定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Aficamten, a next-in-class cardiac myosin inhibitor, improved peak oxygen uptake (pVO2) and lowered resting and Valsalva left ventricular outflow (LVOT) gradients in adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in SEQUOIA-HCM (Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM), a phase 3, multicenter, randomized, double-blinded, placebo-controlled study. OBJECTIVES: The authors sought to evaluate the effect of aficamten on echocardiographic measures of cardiac structure and function in SEQUOIA-HCM. METHODS: Serial echocardiograms were performed over 28 weeks in patients randomized to receive placebo or aficamten in up to 4 individually titrated escalating doses (5-20 mg daily) over 24 weeks based on Valsalva LVOT gradients and left ventricular ejection fraction (LVEF). RESULTS: Among 282 patients (mean age 59 ± 13 years; 41% female, 79% White, 19% Asian), mean LVEF was 75% ± 6% with resting and Valsalva LVOT gradients of 55 ± 30 mm Hg and 83 ± 32 mm Hg, respectively. Over 24 weeks, aficamten significantly lowered resting and Valsalva LVOT gradients, and improved left atrial volume index, lateral and septal e' velocities, and lateral and septal E/e' (all P ≤ 0.001). LV end-systolic volume increased and wall thickness decreased (all P ≤ 0.003). Aficamten resulted in a mild reversible decrease in LVEF (-4.8% [95% CI: -6.4% to -3.3%]; P < 0.001) and absolute LV global circumferential strain (-3.7% [95% CI: 1.8%-5.6%]; P < 0.0010), whereas LV global longitudinal strain was unchanged. Several measures, including LVEF, LVOT gradients, and E/e' returned to baseline following washout. Among those treated with aficamten, improved pVO2 and reduction in N-terminal pro-B-type natriuretic peptide (NT-proBNP) were associated with improvement in lateral e' velocity and septal and lateral E/e' (all P < 0.03), whereas improvement in Kansas City Cardiomyopathy Questionnaire Clinical Summary Scores (KCCQ-CSS) was associated with a decrease in both LVOT gradients (all P < 0.001). CONCLUSIONS: Compared with placebo, patients receiving aficamten demonstrated significant improvement in LVOT gradients and measures of LV diastolic function, and several of these measures were associated with improvements in pVO2, KCCQ-CSS, and NT-proBNP. A modest decrease in LVEF occurred yet remained within normal range. These findings suggest aficamten improved multiple structural and physiological parameters in oHCM without significant adverse changes in LV systolic function. (Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM [SEQUOIA-HCM]; NCT05186818).
引用
- Hegde SM, Claggett BL, Wang X, et al. Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2024. PMID: 39217556. doi:10.1016/j.jacc.2024.08.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。